Discover
CLDI
Calidi Biotherapeutics, Inc.
1.63
4 x 1.62
4 x 1.70
bid
ask
+
0.01
0.62%
50 @ 04:00 PM
1.68 +0.05 (3.07%)
| Ytd | -91.29% | |
| 1y | -97.97% |
1.62
day range
1.70
1.49
52 week range
96.94
| Open | 1.62 | Prev Close | 1.62 | Low | 1.62 | High | 1.70 | Mkt Cap | 750.51K |
| Vol | 159.14K | Avg Vol | 324.83K | EPS | -5.20 | P/E | -0.31 | Forward P/E | -1.57 |
| Beta | 0.57 | Short Ratio | 0.88 | Inst. Own | 2.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.26 | 200-d Avg | 10.66 | 1yr Est | 6.25 |
| Income Statement | |||
| Operating Expenses | 4.19M | ||
| Research and Development Expense | 2.59M | ||
| Selling, General and Administrative Expense | 1.60M | ||
| Operating Income | -4.19M | ||
| Interest Expense | 38.00K | ||
| Income Tax Expense | 4.00K | ||
| Net Income | -4.11M | ||
| Net Income Common Stock | -4.42M | ||
| Net Income Common Stock (USD) | -4.42M | ||
| Consolidated Income | -4.11M | ||
| Earnings per Basic Share | -6.90 | ||
| Earnings per Basic Share (USD) | -6.90 | ||
| Earnings per Diluted Share | -6.90 | ||
| Earning Before Interest & Taxes (EBIT) | -4.07M | ||
| Earning Before Interest & Taxes (USD) | -4.07M | ||
| Preferred Dividends Income Statement Impact | 309.00K | ||
| Weighted Average Shares | 644.00K | ||
| Weighted Average Shares Diluted | 644.00K | ||
| Balance Sheet | |||
| Cash and Equivalents | 6.63M | ||
| Cash and Equivalents (USD) | 6.63M | ||
| Current Assets | 7.35M | ||
| Property, Plant & Equipment Net | 2.10M | ||
| Total Assets | 9.59M | ||
| Debt Current | 1.50M | ||
| Total Debt | 2.26M | ||
| Current Liabilities | 3.84M | ||
| Debt Non-Current | 753.00K | ||
| Total Liabilities | 4.66M | ||
| Accumulated Retained Earnings (Deficit) | -145.73M | ||
| Accumulated Other Comprehensive Income | -22.00K | ||
| Shareholders Equity | 4.93M | ||
| Shareholders Equity (USD) | 4.93M | ||
| Assets Non-Current | 2.24M | ||
| Total Debt (USD) | 2.26M | ||
| Liabilities Non-Current | 820.00K | ||
| Trade and Non-Trade Payables | 900.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 426.00K | ||
| Net Cash Flow from Financing | 5.16M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 1.03M | ||
| Capital Expenditure | -5.00K | ||
| Issuance (Purchase) of Equity Shares | 5.37M | ||
| Issuance (Repayment) of Debt Securities | -215.00K | ||
| Net Cash Flow from Investing | -5.00K | ||
| Net Cash Flow from Operations | -4.12M | ||
| Effect of Exchange Rate Changes on Cash | -7.00K | ||
| Share Based Compensation | 231.00K | ||